Company news
Renalytix Plc (LSE:RENX) news
Renalytix Plc news releases on 6ix. Latest, Oct 5, 2026: Holding(s) in Company
Press releases & updates
Holding(s) in Company
October 5, 2026
Director/PDMR Shareholding (Replacement)
October 2, 2026
Holding(s) in Company
October 2, 2026
Holding(s) in Company
October 1, 2026
Director/PDMR Shareholding
October 1, 2026
Holding(s) in Company
October 1, 2026
Holding(s) in Company
September 30, 2026
Result of GM
September 28, 2026
Investor Presentations
September 25, 2026
Additional CEO Share Purchase
September 16, 2026
New Accounting Ref Date
September 14, 2026
CEO Share Purchase
September 11, 2026
Posting of Circular and Notice of AGM
September 8, 2026
WRAP Retail Offer for up to £1,000,000
September 3, 2026
Capital Access Window - Renalytix plc
September 1, 2026
AIM Rule 17 Disclosure
August 24, 2026
KidneyIntelX® Delivers Unprecedented Two-Year Real-World Outcomes in Diabetic Kidney Disease: No Comparable Risk Assessment Tool Exists
June 30, 2026
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention
May 12, 2026
Key milestones achieved for kidneyintelX.dkd
April 22, 2026
Holding(s) in Company
April 16, 2026
Half-year Report
March 26, 2026
Further CEO Share Purchase
February 13, 2026
Director/PDMR Share Purchase
February 12, 2026
H1 Trading update
February 11, 2026
Three kidneyintelX.dkd Clinical Integrations
January 12, 2026
Result of AGM
December 9, 2025
Plan to Implement ADS Ratio Change
November 25, 2025
Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes
November 18, 2025
Pivotal kidneyintelX.dkd data published
November 12, 2025
Publication of Annual Report & Notice of AGM
November 4, 2025
Audited Full Year Fiscal 2025 Results
November 3, 2025
Confirmation of receipt of £860k R&D tax credits
October 27, 2025
$4m balance sheet improvement with bond conversion
October 10, 2025
CE Mark application submission
October 1, 2025
£7.05m total gross proceeds from Fundraise
September 26, 2025
Update Regarding Forward Guidance
September 24, 2025
Investor Presentation and Revised Revenue Guidance
September 23, 2025
Result of Fundraise
September 22, 2025
Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease
September 15, 2025
Services contract with Joslin and Pharma Partner
July 29, 2025
MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities
July 21, 2025
Partnership with MVP Health Care
July 17, 2025
kidneyintelX.dkd data presented at ERA Congress
June 17, 2025
Growing collaboration with NYKHM
June 3, 2025
First use of KidneyIntelX in new CKD therapy trial
May 20, 2025
Late Breaking KidneyIntelX data show care impact
April 16, 2025
Q3 Trading Update
April 10, 2025
Notice of Interim Results & Investor Presentation
March 12, 2025
Publication in journal (JASN) for kidneyIntelX.dkd
February 6, 2025
Trading Update
January 27, 2025